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INTRODUCTION: Pseudomonas aeruginosa (P. aeruginosa) is one of the primary opportunistic pathogens
responsible for nosocomial infections. Aminoglycosides are an important component of antipseudomonal
chemotherapy. The inactivation of drugs by modifying enzymes is the most common mechanism of aminoglycoside
resistance.
OBJECTIVES: The inactivation of aminoglycosides by modifying enzymes is the primary resistance mechanism
employed by P. aeruginosa. The aim of the present study was to investigate the occurrence of aminoglycoside
resistance and the prevalence of four important modifying enzyme genes (aac (69)-I, aac (69)-II, ant (20)-I, aph (39)-VI)
in P. aeruginosa in Iran.
METHODS: A total of 250 clinical isolates of P. aeruginosa were collected from several hospitals in seven cities in
Iran. Antimicrobial susceptibility tests (using the disk diffusion method and E-tests) were performed for all 250
isolates. In addition, all isolates were screened for the presence of modifying enzyme genes by polymerase chain
reaction.
RESULTS: The resistance rates, as determined by the disk diffusion method, were as follows: gentamicin 43%,
tobramycin 38%, and amikacin 24%. Of the genes examined, aac (69)-II (36%) was the most frequently identified
gene in phenotypic resistant isolates, followed by ant (20)-I, aph (39)-VI, and aac (69)-I.
CONCLUSIONS: Aminoglycoside resistance in P. aeruginosa remains a significant problem in Iran. Therefore, there is
considerable local surveillance of aminoglycoside resistance.
KEYWORDS: Pseudomonas aeruginosa; Antibiotic; Resistance; aac (69)-II; ant (20)-I.
Vaziri F, Peerayeh SN, Nejad QB, Farhadian A. The prevalence of aminoglycoside-modifying enzyme genes (aac (69)-I, aac (69)-II, ant (20)-I, aph (39)-VI)
in Pseudomonas aeruginosa. Clinics. 2011;66(9):1519-1522.
Received for publication on February 1, 2011; First review completed on March 3, 2011; Accepted for publication on May 16, 2011
E-mail: najarp_s@modares.ac.ir / vaziri@modares.ac.ir
Tel.: 00 98 021 82883870
INTRODUCTION
Pseudomonas aeruginosa (P. aeruginosa) is one of the pri-
mary opportunistic pathogens responsible for nosocomial
infections. The most important problem in the eradication
of P. aeruginosa is the frequently observed multi-drug
resistance of the species.1 In addition, P. aeruginosa can
also acquire resistance to various antimicrobial agents,
such as aminoglycosides, b-lactams2 and fluoroquinolones.3
Aminoglycosides are an important component of antipseu-
domonal chemotherapy,4 and they exhibit synergy with
b-lactams.5 Resistance to aminoglycosides occurs via enzy-
matic modification, impermeability, the activity of efflux
pumps (MexXY-OprM),6 the PhoP-PhoQ system,7 ndvB-
dependent biofilm formation,8 and the activity of 16s rRNA
methylases.9 Among these mechanisms, the inactivation of
drugs by plasmid- or chromosome-encoded modifying
enzymes is the most common. These modifying enzymes
include aminoglycoside phosphoryl transferase (aph), ami-
noglycoside acetyltransferase (aac), and aminoglycoside
nucleotidyl transferase (ant).10-12 Four of these enzymes,
encoded by aac (69)-I, aac (69)-II, ant (20)-I, and aph (39)-VI, are
of particular significance because they are among the most
common modifying enzymes present in P. aeruginosa, and
their substrates are the most important antipseudomonal
aminoglycosides. aac (69)-I confers resistance to tobramycin
and amikacin, aac (69)-II and ant (20)-I inactivate tobramycin
and gentamicin, and amikacin is the substrate of aph
(39)-VI.13,14
The aim of the present nationwide study was to
investigate the occurrence of aminoglycoside resistance
and the prevalence of the resistance-modifying enzyme
genes, aac (69)-I, aac (69)-II, ant (20)-I and aph (39)-VI, in P.
aeruginosa isolated from several hospitals in seven Iranian
cities.
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METHODS AND MATERIALS
Collection of bacterial isolates
A total of 250 non-duplicate, clinical isolates of P.
aeruginosa were collected from a nationwide distribution of
several hospitals in seven cities in Iran (Tehran, Shiraz,
Zahedan, Tabriz, Sannandaj, Sari, and Ahvaz) between May
2007 and January 2008. Strain data and the demographic
and clinical data for each patient were regularly forwarded
to our laboratory. The study population was 62% male and
38% female. The specimens were isolated from urine (38%),
wounds (18%), the trachea (18%), blood (10%), sputum (9%),
and other sources (7%). Isolate confirmations were con-
ducted using conventional biochemical tests, and then the
isolates were stored at –76 C˚ in glycerol skim milk broth.
Antimicrobial susceptibility testing
Antimicrobial susceptibility tests were performed using
the disk diffusion method according to Clinical and
Laboratory Standards Institute (CLSI) guidelines15 for three
aminoglycosides [gentamicin (10 mg), amikacin (30 mg), and
tobramycin (10 mg)] and for five other antibiotics [imipenem
(10 mg), piperacillin (100 mg), ticarcillin (75 mg), ceftazidime
(30 mg), and ciprofloxacin (5 mg)]. All drugs were obtained
from Mast laboratories (Merseyside, United Kingdom).
For all 250 isolates, the minimum inhibitory concentrations
(MIC) of amikacin, gentamicin, and tobramycin were
determined using the E-test (Biodisk, Dalvagen, Sweden)
according to CLSI guidelines. P. aeruginosa (ATCC 27853)
served as a control for the disk diffusion and E-tests.
Polymerase chain reaction amplification
Polymerase chain reaction (PCR) was used to screen all 250
isolates for the presence of the modifying enzyme genes, aac
(69)-I, aac (69)-II, ant (20)-I and aph (39)-VI. The total template
DNA for the PCR amplification was extracted from the
supernatant of a mixture of P. aeruginosa cells produced by
the boiling method. PCR amplification was performed using
2.5 mL of the template DNA, 1 mL of each primer,16 19.5 mL
master mix, and 1 mL of Taq DNA polymerase (CinnaGen) in
a total volume of 25 mL. A thermocycler (Mastercycler
gradient; Eppendorf, Hamburg, Germany) was programmed
Figure 1 - The antimicrobial resistance rate of 250 P. aeruginosa isolates as determined by the disk diffusion method AMI: amikacin,
GEN: gentamicin, TOB: tobramycin, IMI: imipenem, PIP: piperacillin, TIC: ticarcillin, CAZ: ceftazidime, CIP: ciprofloxacin.
Table 1 - Aminoglycoside susceptibility profiles according to the disk diffusion method and MIC results (E-test) for 250
P. aeruginosa isolates (according to CLSI guidelines).15
Disk Diffusion1 E-test
2
MIC 50%
(ug/mL)
MIC 90%
(ug/mL).
Resistant Intermediate Susceptible
No. (%) of isolates MIC(mg/ml) MIC(mg/ml) MIC(mg/ml)
Resistant Intermediate Susceptible
–1024
128 64–128 16–64 8 2–4 ,2
Gentamicin 108(43.2) 8(3.2) 134(53.6) 10 41 49 8 98 44 4 64
Tobramycin 95(38) 7(2.8) 148(59.2) 8 45 37 5 103 52 4 64
MIC(mg/ml) MIC(mg/ml) MIC(mg/ml)
MIC 50%
(ug/mL)
MIC 90%
(ug/mL).
.256
–256
128 64–128 32 4–16 ,4
Amikacin 59(23.6) 7(2.8) 184(73.6) 4 17 32 6 134 57 8 128
1. Zone diameter (mm) for gentamicin and tobramycin, R:,12, I:13-14, S:.15; for amikacin, R:,14, I:15-16, S:.17.
2. MIC breakpoint(mg/ml) for gentamicin and tobramycin, R:.16, I:8; S:,4; for amikacin, R:.64, I:32, S:,16.
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with the appropriate conditions. Then, 5 ml of each PCR
product was analyzed by electrophoresis on a 1% (w/v) TAE
agarose gel (Fermentas UAB, Vilnius, Lithuania) containing
0.1 ml/ml ethidium bromide. The amplicons were then
visualized on a UV transilluminator and photographed
(BioDoc-Analyse; Biometra, Goettingen, Germany).
Statistical analysis
All statistical analyses were performed using Statistical
Package for Social Sciences (SPSS) software (version 11.5)
for Windows (x2-test and Fisher’s exact test). P-values of
,0.05 were considered significant.
RESULTS AND DISCUSSION
The resistance rates as determined using the disk
diffusion method are presented in Figure 1. According to
the disk diffusion method, 135 isolates were resistant to
aminoglycosides. The resistance rates according to the E-test
(base on MICs) were as follows: gentamicin 40%, tobramy-
cin 36%, and amikacin 21%. The aminoglycoside suscept-
ibility profiles according to the disk diffusion and E-test
results for the 250 isolates are listed in Table 1.
PCR analysis revealed the absence of resistance genes in
susceptible isolates. The prevalence of aminoglycoside
resistance genes in the 135 resistant isolates (as determined
by the disk diffusion method) was as follows: aac (69)-II was
detected in 36% of the resistant isolates, ant (20)-I was
detected in 28%, aph (39)-VI in 11%, and aac (69)-I was found
in 7% of the resistant isolates (Figure 2). Interestingly,
individual aminoglycoside-resistant isolates carried multi-
ple (two to four) modifying enzyme genes. Six isolates
harbored ant(20)-I and aac(69)-II; three harbored aph(39)-VI
and ant(20)-I; two harbored ant(20)-I and aac(69)-I; and three
isolates harbored ant(20)-I, aac(69)-II and aph(39)-VI. Only one
isolate harbored all four genes.
Several previous studies have examined the occurrence of
aminoglycoside resistance mechanisms in P. aeruginosa
isolated from different countries. The overall incidence of
aminoglycoside resistance found in our study (according to
the disk diffusion test and the E-test) was much higher than
the incidence that has been reported previously in different
countries worldwide.14,16,17 However, Estahbanati and co-
workers reported that 53.3% of clinical isolates from Iranian
burn patients were resistant to amikacin, and 90.7% were
resistant to gentamicin, a result that reveals a high level of
aminoglycoside resistance in their study.18
The aminoglycoside resistance rate was almost as high in
our isolates, and most of the resistant isolates harbored
modifying enzyme genes. In addition, none of the susceptible
isolates harbored these resistance genes. These results high-
light the importance of aminoglycoside-modification-related
mechanisms in aminoglycoside resistance in P. aeruginosa.
Two genes, aac (69)-II and ant (20)-I, were the most frequent
resistance genes observed in these isolates. These results are
similar to what has been observed in different studies in other
countries.19-21 All isolates harboring the aac (69)-II gene were
resistant to gentamicin and tobramycin (100% concordance),
which indicates that aac (69)-II is a significant determinant of
gentamicin and tobramycin resistance in P. aeruginosa. It is
important to mention that we encountered an unexpected
phenotype in some isolates (Table 2). For example, when an
isolate harbored only the aph (39)-VI gene, which has
amikacin as a substrate, resistance to gentamicin, tobramycin,
and amikacin was observed. We presume that the reason for
Figure 2 - Lane 1, 1000 bp DNA size marker; Lane 2, aac(69)-II
(125 bp); Lane 5, aph(39)-VI (800 bp); Lane 7, ant(20)-I (524 bp);
Lanes 8 and 9, aac(69)-I (392 bp).
Table 2 - Prevalence of aminoglycoside modifying enzymes genes and the correlation between these genes and
phenotypic patterns in aminoglycoside resistant P. aeruginosa isolates.
Gene no. of isolates (%)1 Expected resistance2 Observed resistance phenotypes (no. of isolates)3
aac(69)-I 9(7%) TOB,AMI Unexpected resistance to GEN(2)
aac(69)-II 49(36%) GEN,TOB Unexpected resistance to AMI(16)
ant(20)-I 38(28%) GEN,TOB As expected(38)
aph(39)-VI 15(11%) AMI Unexpected resistance to GEN and TOB(2)
aac(69)-II+ ant(20)-I 6(4%) GEN,TOB As expected(6)
ant(20)-I+ aph(39)-VI 3(2%) AMI,GEN,TOB As expected(3)
aac(69)-I+ ant(20)-I 2(1%) AMI,GEN,TOB As expected(2)
ant(20)-I + aac(69)-II +aph(39)-VI 3(2%) AMI,GEN,TOB As expected(3)
aac(69)-II ant(20)-I+ + aph(39)-VI + aac(69)-I 1(,1%) AMI,GEN,TOB As expected(1)
1. According to the disk diffusion method, a total of 135 resistant isolates were identified.
2. AMI: amikacin, GEN: gentamicin, TOB: tobramycin.
3. Described in greater detail in the text.
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this phenomenon might be the action of other resistance
mechanisms, such as impermeability, efflux pumps, or other
types of modifying enzymes. On the other hand, we detected
15 isolates which co-harbored two, three, or four aminoglyco-
side-modifying enzyme genes simultaneously, which is in
contrast to several studies conducted in the USA and Europe,
which reported that the majority of isolates exhibit only a
single aminoglycoside modifying gene.22
Miller et al. brought together the results of several studies
of aminoglycoside resistance in P. aeruginosa carried out
worldwide.22 Their results indicated that in Europe, aac(69)-
II was the most prevalent resistance gene (32.5%), followed
by ant(20)-I (16.9%). These results are in concordance with
our study. In contrast to our results, a Korean nationwide
study of 250 isolates of P. aeruginosa reported that aph(39)-VI,
ant(20)-I, and aac(69)-I were all prevalent, but none harbored
aac(69)-II.16 The difference in the distribution of modifying
enzymes may derive from differences in aminoglycoside
prescription patterns, the selection of bacterial population or
geographical differences in the occurrence of aminoglyco-
side resistance genes.
CONCLUSIONS
In conclusion, although aminoglycosides remain useful
antipseudomonal agents, resistance to these drugs conti-
nues to be a major issue, especially in Iran. Because these
aminoglycoside resistance genes are usually located on
mobile genetic elements (i.e., plasmid, transposon, or
integrons),23,24 there is a growing concern that they could
easily spread and be disseminated among other bacteria.
Integrons that carry gene cassettes encoding both aacs and
carbapenemases will only exacerbate this problem.25 The
design of novel aminoglycosides with stronger affinity for
their targets and resistance to these modifying enzymes is
inevitable,26 and the new generation of anti-Pseudomonas
therapy is forthcoming.27 Aminoglycoside resistance among
clinical isolates of P. aeruginosa promises to become a major
clinical concern in the future, and continuous local surveil-
lance of aminoglycoside resistance is crucial.
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